We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01880320
Recruitment Status : Completed
First Posted : June 18, 2013
Results First Posted : September 9, 2016
Last Update Posted : June 28, 2018
Information provided by (Responsible Party):
Galderma R&D

Brief Summary:

The study hypothesis are based on the assumption that :

  • CD0271 0.3%/CD1579 2.5% Gel provides superior clinical efficacy compared with Topical Gel Vehicle in the overall population and in the subgroup of severe Subjects
  • CD0271 0.3%/CD1579 2.5% Gel applied once daily for up to 12 weeks has an acceptable safety and tolerability profile

Condition or disease Intervention/treatment Phase
Acne Vulgaris Drug: CD0271 0.3% / CD1579 2.5% Drug: CD0271 0.1% / CD1579 2.5% Drug: Topical Gel Vehicle Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 503 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Double-blind, Parallel-group Vehicle and Active Controlled Study to Compare the Efficacy and Safety of CD0271 0.3% / CD1579 2.5% Topical Gel Versus Topical Gel Vehicle in Subjects With Acne Vulgaris
Study Start Date : July 2013
Actual Primary Completion Date : March 2014
Actual Study Completion Date : March 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne

Arm Intervention/treatment
Experimental: CD0271 0.3% /CD1579 2.5% Gel
active arm
Drug: CD0271 0.3% / CD1579 2.5%
Active Comparator: CD0271 0.1% / CD1579 2.5%
Comparator arm
Drug: CD0271 0.1% / CD1579 2.5%
Placebo Comparator: Topical Gel Vehicle
Placebo arm
Drug: Topical Gel Vehicle

Primary Outcome Measures :
  1. Success Rate [ Time Frame: Week 12 ]

    Success was defined as 'Clear' or 'Almost Clear' on the Investigator Global Assessment (IGA).

    Success rate at Week 12 was estimated using multiple imputation approach which is an average of response from multiple imputed datasets.

  2. Changes From Baseline in Inflammatory Lesion Counts [ Time Frame: Baseline - Week12 ]
  3. Changes From Baseline in Non-Inflammatory Lesion Counts [ Time Frame: Baseline - Week 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female, who is 12 years of age or older at Screening visit.
  2. Clinical diagnosis of acne vulgaris with facial involvement.
  3. An IGA of Moderate (3) or Severe (4) at Baseline visit.
  4. A minimum of 20 but not more than 100 inflammatory lesions (papules and pustules) on the face (including the nose) at Baseline visit.
  5. A minimum of 30 but not more than 150 non-inflammatory lesions (open comedones and closed comedones) on the face (including the nose) at Baseline visit.

Exclusion Criteria:

  1. More than 2 acne nodules on the face at Baseline visit.
  2. Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), nodulo cystic acne, or acne requiring systemic treatment.
  3. Underlying diseases or other dermatologic conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments such as, but not limited to, atopic dermatitis, perioral dermatitis or rosacea. This includes clinically significant abnormal findings, uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with the interpretation of the clinical trial results, and/or put the subject at significant risk (according to Investigator's judgment) if he/she participates in the clinical trial.
  4. The subject has received, applied or taken some specified treatments within the specified timeframe prior to the Baseline visit
  5. The subject is unwilling to refrain from use of prohibited medication during the clinical trial.
  6. Use of hormonal contraceptives solely for control of acne.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01880320

Show Show 31 study locations
Sponsors and Collaborators
Galderma R&D
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Galderma R&D
ClinicalTrials.gov Identifier: NCT01880320    
Other Study ID Numbers: RD.06.SPR.18240
First Posted: June 18, 2013    Key Record Dates
Results First Posted: September 9, 2016
Last Update Posted: June 28, 2018
Last Verified: May 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases